Results 51 to 60 of about 5,687 (195)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

Haematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre   +6 more
doaj   +1 more source

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study [PDF]

, 2020
Background: Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic.
Aurran-Schleinitz T., Chen D. -Y., Cheson B. D., D'Sa S., Forconi F., Frigault M. M., Furman R. R., Greenwald D., Hamdy A., Iyengar S., Izumi R., Kastritis E., Kersten M. J., Kothari J., Lee S. K., McCarthy H., Minnema M. C., Mittag D., Owen R. G., Patel P., Rule S., Thomas S. K., Tournilhac O., Walter H., Wei H., Zinzani P. L.   +25 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China

Therapeutic Advances in Hematology
Background: Acalabrutinib is a highly selective, latest generation Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Mengya Li, Xiaoyan Zhong, Chengbin Zhang, Hongli Luo, Li Luo, Yilan Huang, Longyang Jiang   +6 more
doaj   +1 more source

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Current Oncology, 2021
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta   +3 more
doaj   +1 more source

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

British Journal of Haematology, EarlyView.
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup, David A. Cairns, E. Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R. Howard, Anna Hockaday, Julia M. Brown, Sharon Jackson, Natasha Greatorex, Phoebe Templeton, Michael Tupper, David Phillips, Sonam Yaqub, Di Mortimer, David Stones, Piers E. M. Patten, Andrew Rawstron, Peter Hillmen, Talha Munir   +23 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib—findings from three cases

International Journal of Infectious Diseases
Objectives: Ibrutinib, a first-generation covalent Bruton's tyrosine kinase inhibitor (BTKi) was found to be a risk factor for the occurrence of invasive fungal complications.
Marion Blaize, Guillaume Thizy, Alexandre Boissonnas, Anaïs Portalier, Fanny Lanternier, Clémentine de La Porte des Vaux, Felipe Suarez, Marie-Elisabeth Bougnoux, Juliette Guitard, Arnaud Jabet, Nicolas Stocker, Abdelmalek Aoudjhane, Damien Roos-Weil, Arnaud Fekkar   +13 more
doaj   +1 more source